{
    "organizations": [],
    "uuid": "2080096e731ce079d5a4684451bc747c501de8cf",
    "author": "",
    "url": "https://www.reuters.com/article/brief-teva-announces-top-line-results-fr/brief-teva-announces-top-line-results-from-iii-studies-of-reslizumab-idUSFWN1PH0GJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Teva Announces Top-Line Results From III Studies Of Reslizumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 15 PM / Updated 7 minutes ago BRIEF-Teva Announces Top-Line Results From III Studies Of Reslizumab Reuters Staff 1 Min Read \nJan 22 (Reuters) - Teva Pharmaceutical Industries Ltd : \n* TEVA ANNOUNCES TOP-LINE RESULTS FROM PHASE III STUDIES OF SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA \n* TEVA - PHASE III REGISTRATION STUDY EVALUATING SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB (110 MG) IN A PRE-FILLED SYRINGE DID NOT MEET PRIMARY ENDPOINT \n* TEVA - PHASE III CLAIM-SUPPORT STUDY EVALUATING SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB IN PATIENTS WITH OCS-DEPENDENT ASTHMA DID NOT MEET PRIMARY ENDPOINT \n* TEVA -NO NEW SAFETY CONCERNS TO KNOWN SAFETY PROFILE, NO CASES OF ANAPHYLAXIS RELATED TO RESLIZUMAB IDENTIFIED IN REVIEW OF DATA FROM STUDIES Source text for Eikon: Further company coverage:",
    "published": "2018-01-22T15:12:00.000+02:00",
    "crawled": "2018-01-22T16:02:29.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "result",
        "iii",
        "study",
        "reslizumab",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "teva",
        "pharmaceutical",
        "industry",
        "ltd",
        "teva",
        "announces",
        "result",
        "phase",
        "iii",
        "study",
        "subcutaneously",
        "administered",
        "reslizumab",
        "patient",
        "severe",
        "eosinophilic",
        "asthma",
        "teva",
        "phase",
        "iii",
        "registration",
        "study",
        "evaluating",
        "subcutaneously",
        "administered",
        "reslizumab",
        "mg",
        "syringe",
        "meet",
        "primary",
        "endpoint",
        "teva",
        "phase",
        "iii",
        "study",
        "evaluating",
        "subcutaneously",
        "administered",
        "reslizumab",
        "patient",
        "asthma",
        "meet",
        "primary",
        "endpoint",
        "teva",
        "new",
        "safety",
        "concern",
        "known",
        "safety",
        "profile",
        "case",
        "anaphylaxis",
        "related",
        "reslizumab",
        "identified",
        "review",
        "data",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}